Deutsch names Dowshen to head Zelnorm and Diovan business

Share this article:
Deutsch named Matt Dowshen to head the firm's business on Novartis' Zelnorm and Diovan. Dowshen, who joined from JWT New York, where he was senior partner/director-in-charge and co-leader of the DeBeers account, becomes SVP/group account director at Deutsch New York. In addition to the Novartis business, he will head the firm's IKEA account, reporting to Deutsch New York president Val DiFebo.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.